Related Experiment Video

Updated: Oct 12, 2025

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.0K

Coenzyme Q10 in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Randomized Controlled Trial

Fatma Gamal1, Osama El Agami1, Abeer Salamah1

  • 1Department of Pediatrics, Faculty of Medicine, Kafr-Elsheikh University, Kafr-Elsheikh, Egypt.

CNS & Neurological Disorders Drug Targets
|November 25, 2021
PubMed

Insights

Coenzyme Q10 supplementation improved Attention Deficit Hyperactivity Disorder symptoms in children, particularly hyperactivity, and reduced side effects when added to atomoxetine treatment.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pediatrics

Background:

  • Attention Deficit Hyperactivity Disorder (ADHD) is a common neurobehavioral disorder in children with unclear pathogenesis.
  • Oxidative stress is implicated in ADHD development.
  • Coenzyme Q10 (CoQ10), an antioxidant, may offer therapeutic benefits for ADHD.

Purpose of the Study:

  • To evaluate the safety and efficacy of CoQ10 as an adjunctive treatment for ADHD.
  • To assess CoQ10's impact on ADHD symptom severity and treatment-related side effects.

Main Methods:

  • A 6-month, double-blind, randomized controlled trial involving 60 children (6-16 years) with ADHD.
  • Participants were non-responders to atomoxetine and received either atomoxetine plus CoQ10 or atomoxetine plus placebo.
  • Symptom assessment used the CONNERS Parent Rating Scale-Revised (CPRS-48) at baseline and at 1, 3, and 6 months.

Main Results:

  • The CoQ10 group (atomoxetine + CoQ10) showed a 33.87% improvement in CPRS-48 total score, compared to 18.24% in the placebo group (atomoxetine + placebo).
  • Significant reductions in CPRS-48 total score and subscales (learning, impulsive-hyperactive, hyperactivity index) were observed in the CoQ10 group (p<0.001).
  • CoQ10 addition resulted in minimal adverse effects and faster symptom improvement.

Conclusions:

  • Coenzyme Q10 serves as a valuable add-on treatment for ADHD.
  • CoQ10 effectively improves ADHD symptoms, especially hyperactivity.
  • CoQ10 helps mitigate adverse effects associated with atomoxetine therapy.
Abstract

Keywords:
ADHDantioxidantsatomoxetineattentioncoenzyme Q10oxidative stress

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

5.9K
Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol13:09

Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol

Published on: April 1, 2018

10.5K

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
423
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
35
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
29
Oppositional Defiant Disorder01:30

Oppositional Defiant Disorder

A persistent pattern of angry or irritable mood, defiant behavior, or vindictiveness characterizes Oppositional Defiant Disorder (ODD). Symptoms must occur over at least six months, involve interactions with individuals beyond siblings, and meet specific diagnostic criteria to be clinically significant. The disorder affects emotional regulation, social interactions, and behavior, often manifesting early in life and influencing long-term development and functioning.
Diagnostic Criteria and...
192
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
21
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
22